190 related articles for article (PubMed ID: 2171756)
21. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
22. HL-60-1E3, a novel phorbol diester-resistant HL-60 cell line.
Leftwich JA; Carlson P; Adelman B; Hall RE
Cancer Res; 1987 Mar; 47(5):1319-24. PubMed ID: 3028607
[TBL] [Abstract][Full Text] [Related]
23. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
24. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
25. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
26. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
27. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
28. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
Towatari M; Ito Y; Morishita Y; Tanimoto M; Kawashima K; Morishima Y; Andoh T; Saito H
Cancer Res; 1990 Nov; 50(22):7198-202. PubMed ID: 1699657
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW
Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540
[TBL] [Abstract][Full Text] [Related]
34. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
36. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
37. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
Hinds M; Deisseroth K; Mayes J; Altschuler E; Jansen R; Ledley FD; Zwelling LA
Cancer Res; 1991 Sep; 51(17):4729-31. PubMed ID: 1651812
[TBL] [Abstract][Full Text] [Related]
38. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
39. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox ME; Smith PJ
Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
[TBL] [Abstract][Full Text] [Related]
40. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
